Fosamax and Osteonecrosis of the Jaw: Causation and Clinical Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

General Health Context and Legacy of Information Dissemination

The legacy of general health and science information dissemination has long provided a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, discussions of bone health and the management of osteoporosis have been standard topics, often emphasizing the importance of maintaining skeletal integrity through lifestyle measures and pharmacological interventions. This general health framework has historically treated medications such as bisphosphonates as part of a larger narrative of preventive care and chronic disease management, without delving into specific adverse outcomes. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Transition from General Health to Occupational Exposure Concerns

Transitioning from this broad health perspective to a more focused occupational exposure concern requires a shift in analytical lens. While the general health context addresses patient-level risk in clinical settings, the occupational domain examines potential hazards for workers who may encounter these substances during manufacturing, handling, or administration. The bridge between these contexts lies in recognizing that the same pharmacological agents discussed in patient education materials can become points of exposure in industrial environments. This pivot reframes the discussion from therapeutic benefit to potential occupational risk, specifically regarding the association between bisphosphonate exposure and osteonecrosis of the jaw. The focus thus moves from general health maintenance to the specific question of whether workplace exposure to these compounds presents a distinct risk profile that warrants separate consideration in occupational health guidelines.

Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but a serious adverse effect—osteonecrosis of the jaw (ONJ)—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This review examines the clinical evidence linking Fosamax to ONJ, the mechanistic pathways involved, and risk considerations for affected patients. ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and exposed bone in the oral cavity, and diagnosis is based on clinical examination and imaging. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors

The pharmacology of Fosamax involves inhibition of osteoclast-mediated bone resorption, which is the basis for its therapeutic effects in osteoporosis and Paget's disease. However, this same mechanism may contribute to ONJ by suppressing bone turnover in the jaw, impairing the ability to repair microdamage and respond to local infection or trauma. Multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the unique structure and physiology of the jawbone—such as its high remodeling rate and blood supply—may make it particularly vulnerable to bisphosphonate-induced suppression of bone turnover. The mechanistic pathway likely involves accumulation of bisphosphonate in the jawbone, leading to reduced osteoclast activity, impaired bone remodeling, and subsequent necrosis, especially when triggered by dental procedures or infection. The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in clinical trials may be low, and the condition can also occur spontaneously in the absence of bisphosphonate use.

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and it identifies known risk factors such as invasive dental procedures, cancer diagnosis, and concomitant therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, the label does not provide specific guidance on monitoring for ONJ or on the timing of dental evaluations before starting therapy. For affected patients, causation-related considerations are complex. The label notes that ONJ can occur spontaneously, and in clinical trials, the incidence of symptoms was similar between Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This means that establishing a causal link in an individual patient requires careful evaluation of other risk factors, such as dental procedures, cancer, or concomitant medications. The timeline of exposure is also important: symptoms can appear as early as one day or as late as several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Recurrence upon rechallenge with the same or another bisphosphonate provides stronger evidence of causation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ while on Fosamax should discuss with their healthcare provider the risks and benefits of continuing therapy, and dental evaluation is recommended before initiating bisphosphonate treatment, especially in patients with risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the clinical evidence linking Fosamax to osteonecrosis of the jaw?

Clinical evidence supports a causal association between Fosamax and osteonecrosis of the jaw (ONJ). ONJ has been reported in patients taking bisphosphonates, including Fosamax, with risk factors including invasive dental procedures, cancer, and concomitant therapies. The mechanism involves suppression of bone turnover in the jawbone, and the risk increases with duration of exposure. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the known risk factors for developing ONJ while on Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate exposure. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How long after starting Fosamax can ONJ symptoms appear?

The time to onset of ONJ symptoms can range from one day to several months after starting Fosamax. Most patients experience relief after stopping the drug, but recurrence can occur upon rechallenge with the same or another bisphosphonate. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.